HealthTree Logo
search more_vert
App Logo
close
person Sign In / Create Account

Myeloma News

The HealthTree News for Myeloma is a place to learn all about Myeloma in easy-to-understand language. The site features news articles, patient stories, Myeloma basics articles, and clinical trial updates with new content every week.

New, Friendlier Format to View Past Myeloma Round Tables

Feb. 06, 2023

New, Friendlier Format to View Past Myeloma Round Tables

What are Natural Killer Cells?

Feb. 06, 2023

What are Natural Killer Cells?

ASH 2022: MRD Blood-Based Testing in Multiple Myeloma

Feb. 06, 2023

ASH 2022: MRD Blood-Based Testing in Multiple Myeloma

ASH 2022: Risk-Adapted Therapy and MRD-Guided Strategies in Newly Diagnosed Multiple Myeloma

Feb. 02, 2023

ASH 2022: Risk-Adapted Therapy and MRD-Guided Strategies in Newly Diagnosed Multiple Myeloma

Does Quad Induction Therapy Increase Side Effects in Myeloma When Compared to Triplet Therapy?

Feb. 01, 2023

Does Quad Induction Therapy Increase Side Effects in Myeloma When Compared to Triplet Therapy?

HealthTree Connect: A Larger Network for the Myeloma Community

Feb. 01, 2023

HealthTree Connect: A Larger Network for the Myeloma Community

Clinical Trial: Isatuximab in Monoclonal Gammopathy of Renal Significance (MGRS)

Feb. 01, 2023

Clinical Trial: Isatuximab in Monoclonal Gammopathy of Renal Significance (MGRS)

Save the Date(s): Austin, Indianapolis, Raleigh-Durham Myeloma Round Tables, Spring 2023

Feb. 01, 2023

Save the Date(s): Austin, Indianapolis, Raleigh-Durham Myeloma Round Tables, Spring 2023

White Bean Chili

Jan. 31, 2023

White Bean Chili

ASH 2022: Evaluating Responses to SARS-CoV-2 Vaccination Among Patients with Myeloma

Jan. 29, 2023

ASH 2022: Evaluating Responses to SARS-CoV-2 Vaccination Among Patients with Myeloma

ASH 2022:  Talquetamab for Relapsed/Refractory Myeloma Showing Durable Responses

Jan. 24, 2023

ASH 2022: Talquetamab for Relapsed/Refractory Myeloma Showing Durable Responses

ASH 2022: A New Option for High-Risk Smoldering Myeloma Patients

Jan. 24, 2023

ASH 2022: A New Option for High-Risk Smoldering Myeloma Patients

Recent Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Janssen Oncology
Amgen Oncology
Abbvie
Genentech
GSK
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube